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Resumo
A vacinação é uma área de rápidos avanços 
científicos e tecnológicos e as campanhas de 
vacinação estão entre as intervenções mais bem 
sucedidas em políticas de saúde pública. No entanto, 
o potencial de difusão de qualquer tecnologia 
vai muito além de disponibilizar o seu acesso: é 
essencial que a difusão seja compatível com os 
desejos sociais e peculiaridades locais. Esse artigo 
apresenta 2 casos de fracasso na difusão de vacinas, 
em virtude da inabilidade das campanhas de 
vacinação de endereçar aspectos  sociais, culturais 
e políticos. Lições extraídas desses casos sugerem 
que ao invés de focar exclusivamente em aumentar 
a imunidade, as políticas deveriam integrar 
conhecimentos interdisciplinares e promover o 
engajamento social através de processos bottom-up. 
Essas abordagens não são apenas mais capazes de 
aumentar a aceitabilidade e eficácia na difusão das 
tecnologias existentes, mas também de estimular a 
geração (e adaptação) de tecnologias baseadas nas 
capacitações locais.
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Abstract
Vaccination is an area of rapid scientific and 
technological advance and is among the most 
successful public health interventions ever. 
However, for its potential to be met, innovation 
systems should not only make vaccines available: 
it is also essential that delivery systems suit social 
desires and local peculiarities. This work presents 
2 cases of failures in diffusing vaccines, as social, 
cultural and political aspects were not well 
addressed throughout the campaigns. Lessons 
taken from these cases suggest that instead of 
focusing merely on increasing immunity, policies 
should integrate interdisciplinary bodies of 
knowledge and promote social engagement 
through bottom-up processes. These approaches 
are not only keener on improving acceptability 
and efficacy in delivering existing technologies, 
but also to create (and adapt) novelties based on 
local capabilities.
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Introduction
Innovation is a dynamic process, influenced by different sets of agents and institutions. This term is used to describe much more than an outcome, including 
the whole process instead, from creation to diffusion (Schumpeter, 1982). Absorption 
and imitation of novelties created elsewhere are also important forms of diffusion, 
involving underlying progresses on technological capabilities and learning (Teece, 
1988). Diffusion of innovation– as well as its generation – is embedded by uncertainty 
and complexity, and should not be seen as straightforward processes. A systemic 
approach of innovation provides a better understanding about how technical change 
occurs, explaining why some characteristics are continuously reinforced in order to 
keep coherence (Dosi, Nelson & Winter, 1999) or as results from lock-ins (Arthur, 1988). 
All these characteristics combined attribute continuity, cumulativeness, non-linearity 
and path-dependency to innovation processes.
The propensity of nations, sectors or regions to create and diffuse innovation is 
thus influenced by a diverse set of institutional features, reflecting, for instance, their 
cultural, political, social, environmental and economic dimensions (Lundvall, 1992). 
It is consequently difficult to assert policy recommendations for progress as they 
vary according to continuously co-evolving features. Yet, as innovation systems are 
essentially path-dependent, lessons from history help to identify constraints and 
opportunities for future progress.
Along these lines, this work investigates failures in diffusing vaccines. Thanks to 
an unprecedented global effort, there are now billions of dollars available for health 
spending. Immunization campaigns, for example, are increasingly covering all 
countries in the world (Garett, 2007). However, much more than delivering medicines 
is in fact required. Technological diffusion is a rather chaotic process, embedded 
by uncertainty, and shaped by cultural, political and social aspects. Consequently, 
delivery systems should suit social desires and local peculiarities. Most initiatives have 
focused in straightforwardly diffusing “silver bullet” technologies, based on a simplistic 
understanding of innovation systems. Leaving these complexities aside while diffusing 
vaccines can, nevertheless, be extremely counterproductive.
This work will present 2 cases of failures in diffusing vaccines. These cases 
correspond to: measles, mumps and rubella (MMR) in the United Kingdom (UK) and 
oral polio in Nigeria. They were chosen according to their potential to unravel relevant 
evidences in questioning the existence of single, universal technologies that can be 
equally replicated in every context.
The remainder of this paper is structured as follows. The first Section sets 
the research design, which includes the research question, the main hypothesis 
motivating this work, as well as a description of the case study methodology. 
The second section presents the theoretical background. The third Section presents the 
two case studies. The last section explores the empirical evidences; links them to 
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the theoretical background; and finally concludes the paper by describing its 
limitations and suggesting possibilities for future research. 
Research Design
Research Question and Hypothesis
This work aims at investigating the following research question: Are non-
technological aspects (such as social behaviour, culture, geography, politics and 
prevailing institutions) critical to effectively diffuse vaccines?
The main hypothesis behind this question is that major health initiatives are not 
properly tackling diseases, as they are narrowly focused in discovering and making 
“silver bullets”, such as vaccines, available. However, these policies neglect that much 
more is in fact needed than just making vaccines available.
Method
The case study method consists on the intensive investigation – both in depth and 
width – of the object of analysis, in order to provide the most complete understanding 
possible (Yin, 2009). This method is the most appropriate to address the inquiries on 
the efficacy of the diffusion of vaccines in processes that neglected non-technological 
aspects.
This research design is a multiple-case, inductive study. Multiple case studies are 
particularly reliable to answer questions that remain unanswered. This method is 
capable both of generating new concepts – through the unravelling of empirical events 
that were not observed by previous theories – as well as through the investigation of 
hypothesis emerging from conceptual insights. Theories emerging from (or tested by) 
multiple cases are typically more generalizable than the ones derived from single-case 
studies, making them more likely to be validated through other research methods 
(Eisenhardt & Graebner, 2007). This work will explore whether diffusion of medical 
silver bullets are effective, so to test the hypothesis that current global health initiatives 
are not following a good path. 
In order to do that, information on the subject was collected from various 
secondary sources. Instead of dealing with a handful of cases, only two were chosen in 
order to allow scope for descriptions in wide and depth. The cases chosen are namely 
the vaccine controversy in the United Kingdom and oral polio in Nigeria. Both cases 
are about the diffusion of a highly sensitive medical technology: vaccines for child 
immunization. As a consequence, these choices are justified by their relevance, as they 
are particularly capable of contributing with clear and distinct experiences about the 
topic. Triangulation of information extracted from the database was an important tool 
to increase accuracy and as a means of avoiding misinformation. Furthermore, authors 
with different viewpoints on same cases were integrated to the analysis in order to 
improve the reliability of the study. 
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Theoretical Background
Shedding light on innovation
An essential aspect of economic development that has been relegated to the 
periphery of mainstream frameworks consists on comprehending the innovation 
dynamics. While deepening into descriptive ceteris paribus relationships between 
labour and income, neoclassical theories have conceived innovations merely as 
exogenous events. Innovation was understood as spontaneous and sporadic 
discoveries, resulting from embodied creativity and geniality (Solow, 1956). Policies 
according to these frameworks were, therefore, based on recommendations of laissez-
faire and laissez-innover (Freeman & Soete, 2000), as interferences in the market would 
cause negative effects in a system that naturally tends to an optimum equilibrium. 
Moreover, innovation could not be internalized, managed, neither stimulated. In other 
words, equilibrium would be achieved through the invisible hands of the market, and 
innovation could not be handled, while treated as exogenous events. 
In Schumpeter’s theory (1984:113) innovation – and its creative destruction – 
occupied, instead, a prominent place, interpreted as “what capitalism consists in 
and what every capitalist concern has got to live in”. Innovation has been further 
described as a dynamic process, with the capacity of influencing and be influenced by 
a different set of agents, especially by firms. Firms are the main agents of this dynamic, 
as commercialization is an essential feature of innovations (Coriat & Weinstein, 2002). 
The comprehension of the central role played by firms can be understood 
while describing the differences between invention and innovation: terms that are 
commonly treated as synonyms. Invention is an idea, a draft or a model to a new 
product, a service, a design or a process that can be patented, even if not necessarily 
exclusively technological. An innovation, on the other hand, is obtained with the first 
commercial transaction of a novelty, but it is generally used to describe the whole 
process, after creation, through implementation to diffusion (Schumpeter, 1982). 
Furthermore, absorption and imitation of prior novelty created elsewhere are both 
important forms of diffusion – as long as it comes with an underlying progress on the 
organizational learning and technological capabilities (Teece, 1988). 
It has been observed by the literature that innovation should not be seen as a 
singular event, but a rather systematic process (Freeman & Soete, 2000), that goes 
beyond creativity, and is necessarily driven by firms. In addition, innovation dynamics 
are highly uncertain and complex (Tidd, 2001). Uncertainty derives from the fact that 
results of innovative processes cannot be anticipated, while complexity comes from 
the interrelationship between the dimensions involved in these processes: technical, 
social and economic (Kline & Rosenberg, 1986).
Unlike mainstream economics, ‘evolution’ of firms, sectors and nations became 
theoretically more complex, path-dependent and impossible to foresight. Developing 
a general theory of innovation that abstracts from time and space would consequently 
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undermine the utility of the concept both as an analytical and as a policy tool (Lundvall, 
1992; Freeman & Soete, 2000). There is, though, a possibility of understanding 
innovation processes anchored on theoretical background and on history. 
The Systemic Approach of Innovation
The systemic approach considers the complexity, uncertainty and multidirectional 
features of innovation, which “creates kaleidoscopic succession of new possibilities and 
combinations” (Freeman, 1979:226). It analyses the interaction of science, technology, 
and the market, as well as the role of their interaction to drive technical change. Instead 
of examining simple blocks (or variables) and their causal relationships1 the focus has 
shifted to interacting systems. The theoretical tendency thus moved to comprehend 
the properties of these systems and their interactions with underlying institutional 
framings and macro-environmental contexts.
According to Malerba (2004), innovation systems can be characterized by the 
interaction of the three following dimensions: 
I.  Knowledge and technologies: While stressing the importance of learning process, 
creation and diffusion of knowledge and technology, and how dynamic 
technological capabilities (Teece, 1988) and routines (Nelson & Winter, 1982) 
are built, innovation dynamics acquired a cumulative perspective, becoming 
essentially path-dependent. As tacit knowledge (Cowan, David & Foray, 2000) 
is not easily transferred, differences between firms, sectors and nations can be 
justified in a globalized world. 
II.  Actors and networks: Non-market relationships between firms and other agents – 
for instance, their suppliers, consumers, public bodies, universities and research 
institutes – have not only been used to describe innovative dynamics, but also to 
suggest an increasingly important behaviour for their future success (Chesbrough, 
2006). While growing investments in R&D and defensive organizational behaviour 
were important characteristics after the World Wars, many contemporary authors 
have signalized a shift to a more collaborative framework. This would improve 
how they deal with the complexities and uncertainties, enabling them to connect 
tangible and intangible assets of different agents to drive innovations. That is 
the case, for instance, of the triple helix (Leydesdorff, 2000), the open innovation 
(Chesbrough, 2006), the user innovation (Von Hippel, 2001), and the stakeholder 
engagement (Freeman & Reed, 1984). Indeed, new forms of organizations, such as 
spin-offs and joint ventures have emerged in order to cope with these windows of 
opportunities.
III. Institutions: Aggregating inter-institutional features also bring important 
dimensions to understand innovation systems (Castro, 2004). Nelson and Sampat 
(2001), for example, presented how institutions are important for evolutionary 
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economics, in a framework in which institutions are dynamically interrelated 
with physical and social technologies. Understanding how institutions constrain 
or enable (Hodgson, 2005) innovative processes is essential to better understand 
the evolution of firms and nations. Freeman and Perez (1988) and Freeman and 
Louca (2001), both in macroeconomic perspectives, have suggested that the most 
economically successful countries had different sets of supporting institutions 
already in place when they were historically needed, and that these nations were 
capable of appropriating new institutions in order to stimulate their progress. 
It is important to stress that all these characteristics of a systemic approach of 
innovation provide a better understanding about how technical change occurs in 
firms, sectors and nations, as well as to explain why some of their characteristics are 
continuously reinforced in order to keep coherence (Dosi, Nelson & Winter, 1999) or as 
results from lock-ins (Arthur, 1988).
Finally, there are some consensuses about the characterisation of innovation 
processes by most contemporary authors of the evolutionary theory of economics. 
Innovation can be characterized as a continuous, cumulative, systemic, non-linear, 
path-dependent and generally chaotic process (Van De Ven, 1986; Tidd, 2001). It 
consists not only in commercializing new products, services or technologies, neither 
only in generating new processes or business models. It also aggregates processes of 
market diffusion, as well as absorption and imitation of novelties created elsewhere. 
Thus, they can be classified in terms of impacts they generate – commonly categorized 
as radical (disruptive) or incremental (Freeman & Perez, 1988; Christensen, 2000).
Innovation and Learning Systems
One of the most influential sets of writing in evolutionary economics refers to 
the theory on Innovation Systems, which could focus on different levels of analysis, 
such as the regional, national and sectorial (Cassiolato & Lastres, 2005). This concept 
aggregates the patterns of behaviour of firms, the cooperation and competition 
among organizations, and the role of research entities, universities, civil society, the 
prevailing laws and public policies (Lundvall, 1992). All these features are dynamically 
interrelated and continuously coevolving. A systemic approach breaks up with linear 
comprehensions of economic behaviour, highlighting the central role of institutions 
and how their relationship with firms configure “not a congruent and smooth 
evolution, but rather a dynamic form of interplay, accompanied by more or less strong 
tensions” (Coriat & Weinstein, 2002:21).
Focusing on national boundaries (the so-called National Innovation Systems) 
requires analysing “the network of institutions in the public and private sectors whose 
activities and interactions initiate, import, modify and diffuse new technologies” 
(Freeman, 1987:1), and which are “either located within or rooted inside the borders of a 
nation state” (Lundvall, 1992:2). The innovative character of nations and, consequently, 
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their competitive positioning, is influenced by a diverse set of institutional features, 
reflecting their cultural, historical political, social and economic characteristics. 
Certain institutions and national characteristics seem to be more prone to 
configure a solid National Innovation System, constituting a selective environment, 
which minimizes uncertainties and endogenizes technological progress (Albuquerque, 
1997). Instead of becoming standardized with the contemporary globalization, these 
national features became even more important to shape international competitiveness 
(Lundvall, 1988; Porter, 1990). 
The “National Innovation System” approach has indeed being extensively used to 
understand interconnections between technical change, growth and development, 
consequently configuring an important framework to analyse evolution in advanced 
economies. Viotti (2002) nevertheless suggests that this terminology is not appropriate 
to label development of countries below the technological frontier, as proprietary 
innovations play a secondary role in their process of technical change. These countries 
develop mostly through diffusion of foreign technologies and incremental innovations, 
especially focused on processes and on adapting technologies generated elsewhere to 
local realities. It constitutes mainly a learning process and, therefore, the terminology 
National Learning System might be better to describe technical change in latecomers. 
The term ‘learning’ can be used for absorption of already existing techniques, as 
well as to improve the acquired ones. The opportunities and behaviour of national 
firms while generating incremental innovations can be classified as passive or 
active. The first is more associated to absorption that does not require an expressive 
underlying technological effort, such as licensing. The second, on the other hand, 
requires mastering the absorbed technologies, for instance through imitation or 
reverse engineering. Even though both might promote institutional change and 
increase technological capabilities of national firms, the second form of absorption is 
keener on fostering rapid and solid development (Viotti, 2002).  
Finally, it is important to stress that strategies to stimulate passive learning tend 
to be more recurrent in backward countries. However, active learning is a necessary 
step towards reaching more radical pathways in future and, consequently, to generate 
proprietary innovations in the long run (Viotti, 2002). Fostering active learning should, 
consequently, be a priority of national policies of latecomers, requiring institutional 
change and incentives for industrial dynamism. 
What Undifferentiated Innovation Policies do not Recognize?
After analysing the theoretical background from the previous sections, it is 
important to observe that an innovation policy, according to these theories, cannot 
be replicated among different countries, even if they are in similar patterns of 
development. In this case, characteristics from national institutions and firms would 
be neglected, and the systemic dynamics of innovation would be undermined. 
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The non-linear and rather chaotic characteristics of innovation dynamics pose 
certain difficulties for postulating assertive normative policy indications for future 
progress. Possible recommendations for countries differ substantially among their 
patterns of development, most importantly due to the ‘stock’ of capabilities of 
national organizations, as well as to their own peculiarities – such as social, cultural, 
environmental and economic. It is possible, though, to design policies anchored on 
a deep comprehension of each national system, identifying its constraints, as well as 
promoting initiatives that have proven to be keener on succeeding. 
Policies to foster innovation tend, nevertheless, to be advocated through 
technocratic discourses. Although most theorists in this arena emphasise differences 
in instruments and processes in the pursuit of progress, innovation discourses often 
assume undifferentiated and normative policy-recommendations. Indeed, discourses 
of technocratic policy-makers usually endorse utilitarianism and the idea of humans 
as rational choosers. They tend to present an unconditional support to science, 
technology and innovation, arguing that the results are necessarily serving the 
public good (Jasanoff, 2009). Still, the concern here is merely identifying best ways of 
stimulating science and technology, which will shape ‘the future of human race’: no 
scope is left to the other way around.  
Consequently, these narratives obscure the essentially normative character 
of human intentionality upon the directions of progress. Choices are denied to the 
majority of the population while political decisions are justified as ‘based on scientific 
evidences’ or by ‘expert-based assessments’. Deliberately evaluative choices tend, as a 
consequence, to be left aside (Stirling, 2007).
Dissent to technocratic narratives has been treated in the political arena as a ‘march 
of unreason’ (Taverne, 2005), ‘anti-technology anxieties’ (CEC, 2005), or as ‘members of 
the “flat earth society”, opposed to modern economics, modern technology, modern 
science, modern life itself’ (Malloch-Brown, 2001)2. Conversely to these perspectives, 
studies have presented the plurality of dissent values, interests and expectations 
regarding contentious technological pathways – such as GM Crops (Millstone, 2007), 
Stem Cells (Acero & Savaget, 2011) and Nuclear Power (Berkhout & Mackerron, 2009) – 
and how their faithful advocators have casted opponents as Luddites, science deniers, 
irrational, ignorant, misguided or eco-fundamentalists. Laypeople are commonly 
presented as scientifically uninformed, or even as illiterate. Hence, technocratic views 
argue that dissent should not be taken seriously for policy purposes, as the ultimate 
goal of technological progress is given and immutable, and the means to achieve this 
goal is best identified by expert-based assessments. 
Public Health and Diffusion of Vaccines
While less than a decade ago the biggest problem was the lack of resources to 
fight diseases affecting the poor, nowadays, thanks to an unprecedented rise in public 
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and private donations, more money has been shifted to tackle health challenges. 
The World Bank recognised that diseases in poor countries were themselves critical 
obstacles to development, formally announcing the change in 1993, in its annual 
report (Garrett, 2007). Since then, in what concerns an agenda for public health by 
intergovernmental organisations and private donors – such as Bill and Melinda Gates 
Foundation – the tendency is investing in drugs discovery and diffusing the novelties 
around the globe. 
The motivation behind these investments can be many, such as moral duties, 
public diplomacy, and investment in self-protection – as microbes know no boarders 
(Garett, 2007). Most of health aid has been, though, allocated to find “silver bullets” 
for specific diseases: not necessarily the ones that cause more deaths. This notion 
of progress, in a global dimension, favours public health efforts to heal high-profile 
diseases that can be a threat to national security of developed regions (Elbe, 2005). 
This stove-piping tendency reflects particular interests and concerns of donors: not 
the receivers. In other words: “most funds come with strings attached and must be 
spent according to donors’ priorities, politics, and values” (Garrett, 2007:21).
Accordingly, data from the OECD shows that approximately a quarter of all global 
health investments has been allocated to HIV, although this disease constitutes only 
5% of the burden of low and middle income countries, measured by ‘disability adjusted 
life years lost’ (DALYs). This is, for instance, less than deaths caused by respiratory 
infections and perinatal conditions. If the only motivation behind these investments is 
improving global health, these statistics suggest that investments have been allocated 
counterproductively. In fact, much of these investments in finding “silver bullets” 
against high-profile diseases would generate more benefits if shifted to bed nets to 
prevent Malaria and Yellow Fever, family planning, birth assistance to prevent infant 
deaths, and immunisation against pneumonia. Low-profile diseases would, probably, 
receive better care if children in developed countries died from pneumonia, or if 
middle class women in developed countries died in childbirth (England, 2007).
Besides the underfunding of several health hazards, especially the so-called 
neglected tropical diseases, these patterns of investments have other deleterious 
effects. While attempting to find and diffuse drugs for HIV, for example, policies 
tend to separate this disease from sexual and reproductive health, creating “parallel 
structures that constrain the development of health services” (England, 2007:344). 
Moreover, conceiving public health as something ‘objective’ cloaks comprehensive 
understandings of technological diffusion under positivistic and undifferentiated 
pro-innovation discourses. Effectiveness of technological diffusion goes beyond 
making medicines available. Studies on National Innovation/Learning Systems have 
shown that they also require a broad understanding of the local features, traditional 
knowledge, social behaviour, cultural aspects, and so forth. 
Much more than making money available is thus required for global health. The 
starting point for most contemporary initiatives is developing “silver bullets”, such as 
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vaccines, to control or even eliminate the hazards. However, it takes more than drugs to 
deal with healthcare systems. Even when a disruptive vaccine is discovered, sometimes 
it fails in fighting a disease. While all cash tends to flood to R&D or leak away due to 
bureaucracies throughout the operationalization of health policies, there is a lack of 
measures to stimulate other important features. It is notable, for instance, how scarce 
are efforts to foster social engagement; the lack of interdisciplinary approaches while 
dealing with health hazards; as well as the underfunding in low-income countries for 
human skills and infrastructure – such as hospitals, clinics, laboratories. 
The success in diffusing technologies is also related to social understandings 
and desires concerning their own health. According to Garrett (2007:16), no existent 
provisions allow the “poor to say what they want, decide which projects serve their 
needs, or adopt local innovations”. In an opposite direction, health professionals usually 
label dissent to disruptive medical technologies – such as vaccines –as scientifically 
uninformed or even ignorant (Blume, 2006). 
These positivistic perspectives take scientific knowledge as universal truths and 
neglect all the aspects related to technological diffusion. While anti-vaccination 
movements are re-emerging, public health authorities are too focused in finding ways 
of ‘informing ignorant people of the real truth’; instead of integrating lay knowledge 
into vaccination processes, understanding people’s anxieties, and engaging the 
society in public health assessments (Leach & Fairhead, 2007). Therefore, criticism to 
the current policies addressing health challenges goes beyond morality: these policies 
are also essentially counterproductive and lack analytical rigor. 
Learning from Past Experiences
Oral polio in Nigeria
The Global Polio Eradication Initiative (GPEI) is led by the World Health Organization 
(WHO), Rotary International, UNICEF and the US Centre for Disease Control and 
Prevention (CDC) and is the largest public health initiative in the world. GPEI set a target 
to eradicate polio in 125 countries by 2005 and, through the alliance with institutions 
worldwide, it came to achieve high rates of immunizations. There are two varieties of 
polio vaccines: one of which (named Sabin) is given orally and is highly diffused in the 
world, due to its efficacy and to the easiness in handling its vaccination campaigns 
(Eigen, 1997). However, by 2003, polio remained endemic in seven countries, but 
mostly in Nigeria. According to a WHO report (2002), more than 40% of new cases 
of polio in the world in 2002 were in Nigeria, and this high incidence was attributed 
to an insufficient coverage of OPV (oral polio vaccination) programs. Polio was more 
concentrated than ever in predominantly Muslim states in northern Nigeria. These 
were among the few regions in the world to present a rise in incidence, registering a 
fourfold increase in cases by 2001 (WHO, 2002).
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These GPEI targets turned into a far reality in 2003 when Muslim political 
leaders in northern Nigeria – under the umbrella of the Supreme Council for Sharia 
in Nigeria (SCSN) – organized a standstill, as a response to a fear that vaccines were 
deliberately contaminated with HIV virus and anti-fertility drugs. The Polio Eradication 
Initiative in Nigeria was seen as a plan led by western governments to decrease the 
Muslim population in the world. This controversy resulted in a spread of polio within 
Nigerian boarders and to other western and central African countries, diminishing 
the possibilities of meeting GPEI eradication targets and jeopardizing their previous 
accomplishments (Yahya, 2007). 
Historical and political features are essential to understand how the ‘gunpowder 
trail was lit’, propagating a profound distrust in polio vaccination programs. The 
struggle for power between three dominant ethnic groups has been a historical 
source of friction. The federal government, responsible for the campaigns in 2003 was 
not representative of the Muslim region in northern Nigeria. This region also happens 
to have the highest incidence of polio in the country, creating suspicions over the fact 
that Muslims were the main targets of vaccination programs (Renne, 2006). As stated 
by an interviewed Nigerian pharmacist: “This feeling has only intensified following 
events such as the September 11 attacks and the US invasion of Iraq and Afghanistan3”, 
creating a perception that western countries were not fighting specific countries, but 
aiming at extinguishing Muslims (Yahya, 2007). 
While cautioning parents about the dangers of vaccinating their children, political 
leaders boycotted the campaign, propagating fear against western-led initiatives. As 
stated by an inhabitant of a northern region: “We believe that modern-day Hitlers 
have deliberately adulterated the oral polio vaccines with anti-fertility drugs and 
contaminated it with certain viruses which are known to cause HIV and AIDS4”. 
Another reason for refusal was the fear caused by past incidents concerning 
alleged malpractices in a trial of the antibiotic Trovan® from Pfizer, that has been later 
withdrawn from the US market due to serious liver injuries as adverse effects. This drug 
was given for free for 100 children infected with meningitis in 1996 in a region located 
in the north of Nigeria. Instead of a philanthropic action, it was instead a clinical trial 
that allegedly did not fully informed patients of the risks, and to which the death of 
approximately 11 children is attributed (Achebe, 2004). This fact also contributed to 
increase resistance to Western medicines.
Furthermore, the SCSN also claimed the discovery of documents proving that the 
WHO and UNICEF have been involved in the development of anti-fertility vaccines 
administered together with tetanus prevention for more than 20 years. It is interesting 
to observe here how international health programs can lose its “cloak of neutrality, 
acquiring significant political and cultural meanings reflective of a global political 
climate” (Yahya, 2007:192).
Besides the political climate, labelling the polio vaccination refusal in Nigeria 
exclusively as a political controversy is not accurate. There are several reasons regarding 
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social understandings of what health programs should be. A key aspect here is the 
disagreement with the “stupendous spending on polio by donor agencies, in spite of 
the presence of more destructive diseases”5. Non-compliers did not prioritize polio 
immunization. Malaria was a much bigger problem and for them spending resources 
on polio was at least doubtful. It did not make sense, for instance, why the polio vaccine 
was given for free while malaria medicines had to be paid for. As Renne (2006:1866) 
explained: “people were questioning a top-down government decision to promote a 
public health initiative that came from outside, an initiative in which they had no input”.
Therefore, the vaccination program inspired a controversy with cultural, social 
and political dimensions: “beneath the great visions, power struggles and diverse 
motivations remain the perplexed communities of northern Nigeria who strongly 
desire a well-functioning and affordable health care system that takes care of malaria, 
pneumonia, typhoid and polio” (Yahya, 2007:204).
There is also a significant dissatisfaction with the quality of the primary health 
care and the focus on fighting a single disease strengthened non-compliance to the 
program. In fact, a research by Feilden Battersby Analysts (2005) suggested that 
the quantity of human and financial resources invested in fighting a single disease 
was actually contributing to the continuing malfunctioning of the Nigerian primary 
health system. Besides the lack of infrastructure, the top-down health system does not 
allow scope for societal choices upon the targeted diseases and the manners in which 
programs are carried.
Systemic problems of delivery were also responsible for the failure in polio 
vaccination in Nigeria. It was necessary four doses of the vaccine in order to create 
immunity. The government did not have an efficient bookkeeping system and did 
not know exactly who was already vaccinated. This was intensified by the fact that 
the vaccine is administrated orally and, consequently, does not leave any mark on the 
patient (Renne, 2006).
The shortage of human skills was another challenge faced while struggling to 
immunize Nigerians against polio. It was hard to find (and to train) health teams both in 
terms of comprehension about all distinct cultures residing within Nigerian boarders, 
and willingness to take these differences into consideration while delivering the 
vaccines. Some of them, for example, refused to wear veil in Islamic communities and 
did not address properly parental concerns. Others were simply not well trained and 
did not know how to answer questions raised by parents. There were also employees 
of the campaign who did not trust in the immunization program and were there only 
attending to their job demands (Renne, 2006). 
Measles, Mumps and Rubella (MMR) in the UK
The combined shot for measles, mumps and rubella has been well succeeded 
around the world, except in the United Kingdom, where it has been at the core of a 
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tremendous controversy. This controversy has taken place since the late 1990s (Petts & 
Niemeyer, 2004), following a widely publicized report by Wakefield et al (1998) linking 
the vaccine to autism and Crohn’s disease (Cassiday et al, 2006). 
The social mobilization generated by a single article – which described only twelve 
cases signalizing the possibility of adverse effects – gained wide repercussion through 
an extensive coverage by the British media, especially after Wakefield’s declaration in 
a press conference that there was a need for splitting the vaccine into its component 
parts: 1 for each disease (Horton, 2004). These scientific evidences raised by the report 
were not supported by epidemiological studies, neither by public health initiatives in 
the UK. However, MMR uptake since then fell abruptly, especially for the first dose at 
13 months (Cassel et al, 2006). 
This controversy has raised diverse (sometimes polarized) perceptions about 
MMR’s usage. For example, Harris, an advocator of the vaccine, labelled dissent as 
‘outrageous’, while, on the other hand, Stephen Glover, a Daily Mail columnist, labelled 
compliers as ‘assassins’ (Horton, 2004). There were several reasons for the decline in 
MMR immunization that became clear after intensive investigations on parent’s 
attitudes towards child healthcare, as well as discussions on the roles played by the 
media, the government and by science in this controversy (Cassiday et al, 2006). 
An important cause of dissatisfaction among the non-compliers is the fact that, 
despite evidences alerted by Wakefield of side effects caused by the hazardous 
interaction between the 3 viruses in a single shot, the National Health Service did 
not supply separate vaccines (one for each disease). This policy decision was justified 
by the higher costs of providing different shots for each disease. Parents felt that the 
government was risking their children’s lives while prioritizing cost-effectiveness 
instead of dealing with scientific uncertainties (Hargreves et at, 2002).
Accordingly, people tend to trust more in independent analysts than in official 
statements (Burgess et al, 2006). Despite the fact that public researches receive more 
funding (being able to test hypothesis for bigger samples), society tends to see 
research sponsored by the government as biased by interest parties (Horton, 2004). 
This understanding has also gained strength with suspicions about the influence of 
pharmaceutical companies over official governmental statements (Cassel et al, 2006). 
Therefore, while the study of Wakerfield et al (1998) seemed neutral, the government 
was seen as an institution willing to find the cheapest solution possible, with the 
population distrusting its role in regulating risks (Cassiday et al, 2006).
It is important to observe that the longstanding downturn in MMR immunization 
rates is not associated with economic deprivation. Refusal to vaccinate children is 
rather widespread among parents of all social classes and ages (Cassiday et al, 2006). 
Interestingly, in some studies (e.g: Cassel et al, 2006), the non-vaccinators were in 
average better educated than compliers. This reinforces the hypothesis that MMR 
refusal is not due to lack of information or ignorance. Instead, it reflects a wider distrust 
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of the government, recognition of scientific uncertainties, as well as parental anxieties 
toward their children healthcare. 
Indeed, parental understandings of child health are much more complex than how 
it is conceived by British institutions. There are several social and cultural influences on 
health beliefs associated with low MMR uptake. Both compliers and non-compliers 
were supportive to immunization, and both were highly concerned about the safety 
of the vaccine (Cassiday et al, 2006). There is also a sense of parental responsibility in 
assuming personal blame for any harm to their children (Cassel et al, 2006). As reported 
by Fitzpatrick (2004), mothers of autistic children were wracked with guilt of having 
had vaccinated them for MMR and, possibly, being responsible for their disorder.
There is also a high prevalence of vegetarianism, as well as concerns about the 
governmental behaviour in past incidents, such as the BSE (mad cow disease) and the 
GMOs (genetically modified organisms) controversies, suggesting that non-compliers 
might be taking a precautionary approach towards scientific uncertainty. There are 
signals that parents may be delaying MMR vaccination until their risks are better 
elucidated or better options come up (Cassel et al, 2006). 
Furthermore, while studies advocating for vaccination indicated misbehaviour 
of the British press – suggesting that they were only emphasizing the viewpoints 
raised by Wakefield et al (1998) – Cassiday et al (2006) demonstrated that adverse 
media coverage had little impact on parental attitudes to MMR. Media channels were 
identified as important sources of information, but there is no evidence suggesting 
that parents passively agreed with the messages. There was, on the other hand, an 
important role played by social networks in reinforcing health beliefs. Accordingly, 
the impact with personal face-to-face engagement with health professionals is 
considerably high (Petts & Niemeyer, 2004).
Several studies also confirmed the influential role played in the refusal context, 
by homeopathy and lay concepts of immunity – that suggested a possible overload 
of viruses for a child, jeopardizing their health. According to the work published by 
Cassel et al (2006), 86% of non-compliant mothers strongly agreed that ‘the MMR is 
too much in one go’. These mothers appear to be well informed, with high interest in 
health-related issues, as well as concerned about food related choices. 
Again, traditional theories on health would advocate for empowerment of 
marginalized and ignorant people while, in the case of MMR, awareness is associated 
to reduced acceptance. This suggests the importance of health programs to engage 
with concepts and beliefs that western science rejects. Informing a public that have 
a well-grounded dissonant scientific view is unpractical and raises ethical questions 
about dealing with consent in a plural society (Cassel et al, 2006).
Analysis and Final Discussion
Global health initiatives have recognized immunization as the most affordable 
and effective means of reducing child mortality and contribute to poverty alleviation. 
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Vaccination campaigns are often designed by global organizations to be replicated 
among different settings, though the journey from global planning to local reality can 
be vulnerable and unpredictable (Yahya, 2007). Criticising global health initiatives by 
indicating failures in diffusing “silver bullet” technologies here is not a “Luddite” refusal 
of technological advancements. The cases described in the previous section were 
costly in economic and human terms, but are particularly insightful to understand 
the complexities circumscribing technological diffusion, opening up discussions on the 
importance of dialogue and inclusiveness for public health campaigns.
The first lesson here answers to the research question. Both cases have shown 
severe failures in diffusing vaccines as they neglected social, political and cultural 
dimensions. Technological diffusion, especially one that targets such a sensitive 
issue (child health), is far from being straightforward. Several characteristics around 
vaccination refusal, nonetheless, are often masked as ignorance, lack of information or 
misunderstanding. For instance, the governmental positioning in the UK towards the 
MMR failure has been of blaming dissent scientific perspectives and the role of media 
in spreading ‘the untruth’, while the failure in Nigeria was seen exclusively as a matter 
of political instability and religious conflicts. 
Rather than delegitimizing vaccination refusal, the previous section has shown 
that reasons for vaccination failures in the UK and Nigeria go much beyond how they 
have been casted. Parental anxieties need to be taken comprehensively, as they are 
embedded by past experiences regarding science and the government behaviour, 
and also with what is essentially normative: what is desired for healthcare (Fairhead 
& Leach, 2007). 
In fact, there are several similarities across MMR and Polio refusal – even in settings 
that are so culturally, socially, politically and economically different. Observing the 
complexity of the cases and evidencing their similarities have great implications to 
governance mechanisms in diffusing medical technologies. These similarities are 
summarized in the table below.
Criteria Polio in Nigeria+ MMR in the UK
C1 Drug centred approach to immunize children
C2 Administrative, top-down governance 
C3 Bureaucratic decision making 
C4 No scope for societal choices on what should be prioritized for health care
C5 Societal mistrust on governmental behaviour
C6 Prevalence of medical knowledge, without integrating interdisciplinary theories and lay understandings on healthcare
C7 Expert opinion and administrative decisions were paramount
Table 1– Similarities across Cases
Source: elaborated by the author
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These similarities suggest a clash between global objectives and societal priorities 
and understandings on healthcare. Though sometimes it is more costly than just 
making medicines available, commitments to people-centred approaches are more 
promising, turning disease-specific vaccination campaigns into broader healthcare 
programs. This observation confirms the hypothesis that healthcare initiatives tend to 
be focused in diffusing technologies. 
A challenge of technological diffusion is responding to different needs and 
vulnerabilities. Single approaches for mass immunization are nonetheless backed by 
particular scientific viewpoints and, consequently, intertwined with institutional and 
power relations (Jasanoff, 2005). Addressing health cannot be dissociated from people’s 
priorities, understandings, and, therefore, it is essential to promote inclusiveness and 
interdisciplinarity in its governance. The table below summarizes the main differences 
between bottom-up and top-down healthcare approaches.
Accordingly, virtually no provisions exist to allow the “world’s poor to say what 
they want, decide which projects serve their needs, or adopt local innovations” (Garett, 
2007:16). There is a lack of systemic approaches matching societal needs with financial 
resources that are available. Policy approaches that are dismissive of the conceptual 
worlds of individuals and insensitive to connect clinic attendance, health trajectories 
and social relations, are not keen on succeeding in diffusing vaccines. This might be 
increasingly important, as global political tensions and scientific and technologic 
uncertainties will likely intensify in future (Fairhead & Leach, 2007).
Indeed, several contemporary controversies regarding vaccination programs have 
been evidenced in different contexts in the last years. That is the recent case of the “no 
jab no play” controversy in Australia6and the killing of healthcare officials in Pakistan7. 
The recurrence of vaccination refusal and the mishandling of governments towards 
non-compliance demonstrate the necessity of increasingly take into account bottom-
Criteria Top-Down Global Health Campaigns Bottom-up Health Care
C1  - Context One size fits all Recognizes the importance of contex-t-specific solutions
C2 - What Drug-centred approach
Patient-centred approaches, with 
treatments based on social anxieties 
and needs
C3 - Why Ease of implementation & scaling-up More inclusive to local specificities
C4 - How Drug development and undifferentiated campaigns for mass vaccination
Combines social engagement, interdis-
ciplinary knowledge, and diffusion of 
medical technologies
Source: elaborated by the author
Table 2 – Top-Down vs. Bottom-Up HealthCare Approaches
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up approaches, which would integrate people’s anxieties, beliefs and priorities with 
interdisciplinary bodies of knowledge.
People, in general, want functioning health system addressing the wider range 
of diseases they prioritise, and want to be confident that healthcare teams share 
their interests. It is essential to shift towards pluralistic approaches that are not 
overwhelmingly reliant on ‘experts’, but rather patient-centred, integrating scientific 
knowledge with what is desired by the public (Fairhead and Leach, 2007). In other 
words, instead of getting trapped into an unproductive ‘expert vs public’ debate, the 
challenge is to embrace the different forms of expertise offered, to view these as a 
resources rather than burdens.
A relevant issue here regards appreciating complementarities between 
traditional healthcare and alternative therapies – e.g: indigenous healing knowledge, 
homeopathy, and food related concerns. These alternatives are not opposite to 
allopathic medicine and complementarities can be seen as opportunities for creating 
solid and better accepted healthcare systems (Fairhead and Leach, 2007). 
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Mobilizations, such as the refusal to Polio and MMR, are also consonant with 
arguments in favour of democratization of science and technology. If these are to meet 
public needs, policies should foster democratic decisions on the directions healthcare 
should pursue, opening-up appraisal to different values, interests and desires. The 
similarities observed between the two cases of failures in diffusing “silver bullet” 
technologies are evidences of the importance of deliberately evaluative approaches 
to technological governance (Stirling, 2007). As shown by the cases, inclusive and 
bottom-up governance settings are not only a matter of public desirability, but rather 
of analytical rigor, as the diffusion of technologies are keener on failing when driven 
by top-down processes. Social engagement throughout healthcare processes can 
also stimulate local innovativeness and learning, as new ‘solutions’ based on their own 
capabilities might arise.
It is important, though, to stress that this work was limited to two case studies, 
capable of contributing with insightful experiences to address the research question. 
Although examples arose in different settings, they share similarities that provide 
important implications for governance of healthcare systems as well as of science and 
technology. This work also confirmed a hypothesis that directions pursued by major 
health initiatives are lacking efficacy. The imperative for democratization of health 
related choices is not only a matter of desirability, but also of analytical rigor, as top-
down, drug-centred approaches are keener on failing. 
Ways forward in deepening scientific knowledge about this topic could use 
different regions, so to test their differences towards health programs. Moreover, other 
healthcare failures could be overlapped with the two cases presented in this work, 
so to check if they also share same similarities and, consequently, increase analytical 
robustness. Future quantitative research on that topic would also contribute to 
understand the connections between variables in a wider sample. 
Notas 
1 Such as the push-pull controversy in linear models of innovation
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